Breaking News

Biogen Licenses CEVEC AAV Mfg. Technology

Biogen gains rights to ELEVECTA Technology for manufacturing of gene therapy products.

By: Contract Pharma

Contract Pharma Staff

CEVEC Pharmaceuticals GmbH (CEVEC) signed a license agreement with Biogen Inc. for the use of CEVEC’s ELEVECTA Technology for the manufacturing of adeno-associated virus (AAV) vectors for gene therapy applications.   Under the agreement, Biogen has a non-exclusive license for CEVEC’s ELEVECTA Technology with the rights to use the technology across its portfolio of gene therapy products. CEVEC is eligible for technology access and milestone fees, including clinical development and commercial mi...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters